PTC logo PTC +
PTC
+

PTC (PTC) Business News

Track PTC in real time with a live news feed covering PTC stock news, official press releases, company announcements, and an archive of historical PTC news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

PTC's Creo and Windchill Solutions Selected for Product Development across Fisica Applied Technologies

PRNewsWire

8:30 AM | Tuesday | Sep 15, 2026

news photo
Loading...

Standardizes on Creo CAD and Windchill PLM across multiple business units and locations Supports design consistency, configuration control, and traceability for complex defense programs Supports both near‑term operational needs and long‑term growth BOSTON, Sept. 15, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that Fisica Applied Technologies, Inc., a leading defense products manufacturer of airborne and ground-based antennas; electromagnetic systems and simulators; and ruggedized batteries, has selected the PTC Creo® computer-aided design (CAD) and Windchill® product lifecycle management (PLM) solutions for product design and development across its engineering environment.

Read full article redirect
8:30 AM | Tuesday | Sep 15, 2026

PTC's Creo and Windchill Solutions Selected for Product Development across Fisica Applied Technologies

PRNewsWire

Standardizes on Creo CAD and Windchill PLM across multiple business units and locations Supports design consistency, configuration control, and traceability for complex defense programs Supports both near‑term operational needs and long‑term growth BOSTON, Sept. 15, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that Fisica Applied Technologies, Inc., a leading defense products manufacturer of airborne and ground-based antennas; electromagnetic systems and simulators; and ruggedized batteries, has selected the PTC Creo® computer-aided design (CAD) and Windchill® product lifecycle management (PLM) solutions for product design and development across its engineering environment.

Read full article arrow
News Thumbnail
8:30 AM | Tuesday | Sep 15, 2026

PTC's Creo and Windchill Solutions Selected for Product Development across Fisica Applied Technologies

PRNewsWire

Standardizes on Creo CAD and Windchill PLM across multiple business units and locations Supports design consistency, configuration control, and traceability for complex defense programs Supports both near‑term operational needs and long‑term growth BOSTON, Sept. 15, 2026 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced that Fisica Applied Technologies, Inc., a leading defense products manufacturer of airborne and ground-based antennas; electromagnetic systems and simulators; and ruggedized batteries, has selected the PTC Creo® computer-aided design (CAD) and Windchill® product lifecycle management (PLM) solutions for product design and development across its engineering environment.

Read full article arrow
News Thumbnail
3:52 AM | Saturday | Sep 12, 2026

PTC Inc.: The Market Is Pricing In Stagnation At 16x Earnings

Seeking Alpha

PTC Inc. trades at a depressed valuation after a 37% sell-off, despite underlying ARR growth of 9% and raised full-year guidance. Reported revenue masks business strength; deferred ARR for fiscal 2027 is double last year's level, and improved sales execution is driving retention and competitive wins. New pricing structures embed 3%-4% annual increases, providing a gradual tailwind as contracts renew over the next several years.

Read full article arrow
News Thumbnail
3:07 AM | Thursday | Sep 10, 2026

Amundi Has $107.65 Million Stock Position in PTC Inc. $PTC

Defense World

Amundi reduced its holdings in PTC Inc. (NASDAQ: PTC) by 45.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 947,662 shares of the technology company's stock after selling 777,893 shares during the period. Amundi owned approximately 0.
87% of

Read full article arrow
News Thumbnail
12:57 PM | Wednesday | Sep 9, 2026

PTC Inc. (PTC) Presents at Citi's 2026 Global TMT Conference Transcript

Seeking Alpha

PTC Inc. (PTC) Presents at Citi's 2026 Global TMT Conference Transcript

Read full article arrow
News Thumbnail
3:56 AM | Tuesday | Sep 8, 2026

Hsbc Holdings PLC Purchases 231,563 Shares of PTC Inc. $PTC

Defense World

Hsbc Holdings PLC grew its position in PTC Inc. (NASDAQ: PTC) by 65.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 587,782 shares of the technology company's stock after purchasing an additional 231,563 shares during the

Read full article arrow
News Thumbnail
12:36 PM | Friday | Aug 28, 2026

PTC Inc. (PTC) Up 16.6% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Aug 27, 2026

PTC Therapeutics to Participate in Upcoming Investor Conferences

PRNewsWire

WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare Conference Thursday, Sept.

Read full article arrow
News Thumbnail
8:00 AM | Monday | Aug 24, 2026

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

PRNewsWire

– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug.
25-28.

Read full article arrow
News Thumbnail
5:31 AM | Monday | Aug 24, 2026

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

Seeking Alpha

PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT's lead asset, has driven rapid revenue growth, accounting for 63% of product revenue and expanding across major global markets. ST-920, acquired from Sangamo, is a late-stage gene therapy for Fabry Disease; FDA approval could significantly enhance PTCT's valuation.

Read full article arrow
News Thumbnail
11:02 AM | Sunday | Aug 16, 2026

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal

MarketBeat

PTC Therapeutics NASDAQ: PTCT plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.

Read full article arrow
News Thumbnail